1. Introduction {#s0005}
===============

The prevalence of CAD increased drastically in rural and urban India almost to the tune of two to four fold over the turn of the century. Though half of the Asian Indians are lifelong vegetarians, the CAD risk is similar when compared to non-vegetarians ([@b0040]). In the South Asian populations, the escalated rate of disease burden due to CAD is primarily responsible to dyslipidemia ([@b0035]). Dyslipidemia is referred to as derangements of one or more of the lipoproteins; elevated levels of total cholesterol, low density lipoprotein (LDL) cholesterol and/or triglycerides, or low levels of high-density lipoproteins (HDL) cholesterol ([@b0085]). Physical inactivity, body composition, genetic predisposition and diet are considered as the determinants of dyslipidemia in Asian Indians ([@b0045]). Management of CAD involves the pharmacological management of risk factors like dyslipidemia, hypertension etc. along with the more powerful strategy of non-pharmacological management using diet modifications and nutrition management aimed at improving dyslipidemia along with improving the quality of life with proper care of physiological and nutritional health ([@b0080]). Dietary recommendations in dyslipidemia includes cereals, millets, pulses and legumes along with low glycemic index foods like flour, root vegetables such as Yam, Tapioca, and Colocasia. Traditional food items of Indian community had extensively utilized the wealth of natural nutritional sources. Traditional treatment systems like Ayurveda & Siddha incorporated and endorsed the use of these drugs as a dietary and a therapeutic agent in disorders originated from derangement of three humors (viz. vata, pitta and kapha). Among the commonly used articles of food items throughout the Indian subcontinent includes the green gram and the Elephant foot yam. Even the tribal populations scattered around India also included these items in their regular diet. The green gram (*Vigna radiata* (L.) R. Wilczek., Family Fabaceae, commonly called Mungbean or *Mudga* contain balanced nutrients including protein, dietary fiber and bioactive phytochemicals ([@b0120]). The phytosterols contained in the sprouted mung bean powder lowers blood fat by competitively bind to the enzymes responsible for esterification of cholesterol ([@b0105]). The Elephant foot yam (*Amorphophallus paeoniifolius* (Dennst.) Nicolson, belonging to the family Araceae, commonly called surana or sweet yam is an underground tuber which is a staple vegetable of Indians. The corm of *Amorphophallus* is a rich source of phytosterols and has proved hepatoprotective activity comparable to that of Silymarin ([@b0065]) along with significant anti-oxidant property. However, these two plant sources have been utilized traditionally as a balanced diet in lowering lipid levels since antiquity. So, a combination of sprouted Mung bean powder and *Amorphophallus* corm provides a future perspective of non-pharmacological management of dyslipidemia. Considering the above facts, a study has been planned to evaluate the effect of the powder of sprouted mung bean and purified *Amorphophallus* corm on serum lipid levels in albino rats of Wistar strain receiving cholestyramine resin as standard drug.

2. Materials and methods {#s0010}
========================

2.1. Drug {#s0015}
---------

Seeds of Green gram were purchased from local market and were washed and cleaned thoroughly to remove any foreign matter and were soaked in twice the quantity of distilled water for 4 h. The seeds were again rinsed with distilled water and were kept in sterile petridishes in a single layer over sterile muslin cloth moistened with distilled water. The dishes were placed in a seed germinator (Single chamber) (Indosaw Germinator, Haryana, India) and incubated at 25 °C temperature and a relative humidity of 90% for a period of 48 h. After germination the seeds were dried in an oven maintained at 60 °C overnight and cooled to room temperature in desiccators. The seeds were later milled using a Mini Dal Mill Lab Model (Osaw Industrial Products, Haryana, India) at 20,000 rpm using size 30 mesh ([@b0075]).

The consumption of raw Yam tubers produced several adverse reactions in the form of pruritus in oral cavity and throat. Keeping this in mind, the Yam was purified as per the accepted protocol of boiling in buttermilk as followed in the system of Ayurveda. Corms of yam were washed, peeled and sliced into thin uniform slices into a vessel containing distilled water. The pieces were boiled in an open vessel with butter milk till the pieces were properly cooked and soft. The excess butter milk was drained off and the pieces of yam were dried in an oven at 60 °C and were cooled in desiccators and were milled to a fine powder as in green gram.

The two powders were mixed in 1:1 proportion (w/w) and thoroughly mixed till the mixture was homogenized. The mixture was stored in airtight containers till the beginning of the study. The dose was fixed from a standard surface area conversion table ([@b0095]). The corresponding human doses as per the references form *Sarngadhara Samhitha* ([@b0090]) of 12 g per day was converted to the corresponding animal dose of 0.108 g per 100 g body weight as the effective dose (ED). The doses 0.054 g and 0.216 g per 100 g body weight were considered as the Half dose (HD) and Double dose (DD) respectively. Drugs were administered after reconstituting in 10 ml of normal saline with the help of an intragastric tube.

2.2. Experimental design {#s0020}
------------------------

The experiment was carried out after obtaining permission from the IAEC (No: IAEC/DRB18). A total of 30 albino rats of Wistar strain weighing between 150 and 200 g were used for the study. The animals were given a fortnight to acclimatize to the laboratory environment. The animals were housed in standard polythene cages with 12 h light and dark cycles and were fed on standard rat feed (Sai Durga Feeds, Bangalore, Karnataka). Water was given *ad libitum* throughout the experiment. All animals were taken care of as per the CPCSEA guidelines. All animals were weighed, randomized and properly marked for identification before the start of the study.

The experiment was completed in 30 days. Before the commencement of the study, the animals were divided into five groups of six animals each and they were fasted for 20 h by withdrawing food and not water. On the morning of the first day of experiment, blood samples were drawn from each animal under light ether anesthesia by retro-orbital puncture. Then, first dose of medicine was given to each animal depending on the group they belong to.**Group I:** (Normal Control Group): Normal saline 10 ml/kg body weight/day.**Group II:** (Standard Group): Cholestyramine resin 5 mg/kg body weight/day.**Group III:** (Half Dose Group): Drug powder at a dose of 540 mg/kg body weight/day.**Group IV:** (Effective Dose Group): Drug powder at 1080 mg/kg body weight/day. and**Group V:** (Double Dose Group): Drug powder at 2160 mg/kg body weight/day.

The drugs were administered for a period of 30 days. On the last day of the study, the animals were fasted for 20 h by withdrawing food and not water. Blood was collected at the end of the study by retro-orbital puncture after light ether anesthesia.

2.3. Method of blood collection {#s0025}
-------------------------------

Blood was collected from each animal at the beginning and end of the study. Blood was collected with the help of a capillary tube from the orbital sinus after engorging the retroorbital plexus by pressing the thumb behind the angle of the jaw. The blood were transferred to a tube and centrifuged for 10 min at 3000 rpm to collect the serum. After separating the serum, total Serum Cholesterol (TC), Triglycerides (TG), Low Density Lipoprotein Cholesterol (LDL), Very Low Density Lipoprotein Cholesterol (VLDL), High Density Lipoprotein Cholesterol (HDL), Castelli's Risk Index-I (CRI-I), Castelli's Risk Index-II(CRI-II), Non-HDL cholesterol/HDL ratio, Atherogenic Coefficient (AC) and Atherogenic Index of Plasma (AIP) were estimated ([@b0075]). Serum LDL and VLDL were estimated using Friedwald's formula ([@b0015]). Atherogenic Index as well as percentage of protection was also calculated ([@b0020]).

2.4. Statistical analysis {#s0030}
-------------------------

Data obtained were subjected to One-way Analysis of Variance (ANOVA) followed by Dunnet's multiple comparison tests as post hoc test using SPSS Statistical package version 16.0. The chosen level of significance was 5% (p \< 0.05).

3. Results {#s0035}
==========

The results of all serum lipid estimation were reported as Mean ± SEM (Standard error of mean) of 6 animals in each group. The difference between the groups were analyzed using one-way ANOVA, followed by Dunnet's multiple comparison test as the post hoc test if the ANOVA showed significance at 5% level (p \< 0.05). The different serum lipid parameters at the end of 30 days are as shown in [Table 1](#t0005){ref-type="table"}. [Table 2](#t0010){ref-type="table"} shows the HDL Ratio, Atherogenic Indices and Percentage protection in each treated group.Table 1Effect of drug on serum lipid levels.GroupTotal cholesterolTriglyceridesHdlLdlVldlNormal141.0 ± 5.1393.66 ± 2.7130.83 ± 2.791.66 ± 5.718.5 ± 0.56Standard96.8 ± 3.6[a](#tblfn1){ref-type="table-fn"}80.5 ± 3.91[a](#tblfn1){ref-type="table-fn"}32.0 ± 3.57[d](#tblfn4){ref-type="table-fn"}48.83 ± 3.51[a](#tblfn1){ref-type="table-fn"}16.0 ± 0.68[b](#tblfn2){ref-type="table-fn"}Effective dose103.0 ± 2.13[b](#tblfn2){ref-type="table-fn"}74.33 ± 4.68[a](#tblfn1){ref-type="table-fn"}49.3 ± 3.35[a](#tblfn1){ref-type="table-fn"}38.83 ± 3.5[b](#tblfn2){ref-type="table-fn"}14.83 ± 0.91[a](#tblfn1){ref-type="table-fn"}Half dose115.83 ± 5.8[d](#tblfn4){ref-type="table-fn"}80.83 ± 5.12[d](#tblfn4){ref-type="table-fn"}38.3 ± 2.21[d](#tblfn4){ref-type="table-fn"}58.66 ± 7.3[d](#tblfn4){ref-type="table-fn"}16.2 ± 1.07[d](#tblfn4){ref-type="table-fn"}Double dose98.50 ± 2.06[a](#tblfn1){ref-type="table-fn"}78.33 ± 6.06[a](#tblfn1){ref-type="table-fn"}39.0 ± 1.74[a](#tblfn1){ref-type="table-fn"}55.33 ± 9.5[a](#tblfn1){ref-type="table-fn"}15.66 ± 1.20[a](#tblfn1){ref-type="table-fn"}F Ratio8.25[c](#tblfn3){ref-type="table-fn"}4.177[c](#tblfn3){ref-type="table-fn"}4.936[c](#tblfn3){ref-type="table-fn"}5.857[c](#tblfn3){ref-type="table-fn"}4.04[c](#tblfn3){ref-type="table-fn"}Df4, 254, 254, 254, 254, 25[^1][^2][^3][^4][^5]Table 2Atherogenic index and percentage protection in different groups.Cri iNon-hdl c/hdlCri iiTg/hdlPlasma ai% protectionNormal4.6 ± 0.153.6 ± 0.223.0 ± 0.373.0 ± 0.340.18 ± 0.040Standard3.0 ± 0.18[c](#tblfn7){ref-type="table-fn"}2.0 ± 0.18[c](#tblfn7){ref-type="table-fn"}1.5 ± 0.27[a](#tblfn5){ref-type="table-fn"}2.5 ± 0.1[d](#tblfn8){ref-type="table-fn"}0.24 ± 0.01[d](#tblfn8){ref-type="table-fn"}39.4Effective dose2.1 ± 0.07[c](#tblfn7){ref-type="table-fn"}1.1 ± 0.02[c](#tblfn7){ref-type="table-fn"}0.8 ± 0.13[c](#tblfn7){ref-type="table-fn"}1.5 ± 0.14[b](#tblfn6){ref-type="table-fn"}0.29 ± 0.01[a](#tblfn5){ref-type="table-fn"}51.2Half dose3.0 ± 0.19[c](#tblfn7){ref-type="table-fn"}2.0 ± 0.11[c](#tblfn7){ref-type="table-fn"}1.5 ± 0.09[b](#tblfn6){ref-type="table-fn"}2.1 ± 0.29[d](#tblfn8){ref-type="table-fn"}0.24 ± 0.02[d](#tblfn8){ref-type="table-fn"}45.8Double dose2.5 ± 0.08[c](#tblfn7){ref-type="table-fn"}1.5 ± 0.27[c](#tblfn7){ref-type="table-fn"}1.4 ± 0.12[b](#tblfn6){ref-type="table-fn"}2.0 ± 0.25[a](#tblfn5){ref-type="table-fn"}0.26 ± 0.01[d](#tblfn8){ref-type="table-fn"}33.7F ratio42.0125.8812.775.613.48--Df4, 254, 254, 254, 254, 25--[^6][^7][^8][^9][^10]

Results reveal that there was a significant reduction in all the lipid parameters (p \< 0.05) except HDL after 30 days of administration of the drug when compared to the normal animals. HDL showed significant elevation (p \< 0.05) than the normal rats. The lipid lowering capability of the drug combination (p \< 0.05) along with its potential to elevate HDL (p \< 0.05) in rats when given at a dose of 1080 mg/kg body weight (Effective dose) and 2160 mg/kg body weight (Double dose) is proved. The Half dose of 540 mg/kg body weight showed insignificant results (p \> 0.05) in lowering lipid levels as well as raising the HDL levels.

The Standard drug cholestyramine resin at a dose of 5 mg/kg body weight showed significant reduction (p \< 0.05) in all serum lipid levels, but the drug was unable to elevate the HDL significantly (p \> 0.05) when compared to the normal rates. The effective and double doses of the drug (1080 mg/kg and 2160 mg/kg body weight respectively) significantly reduced the Atherogenic Indices (p \< 0.01) and significantly elevated the HDL Ratio (P \< 0.01) and Percentage protection (P \< 0.05) than the normal rats. The Hypolipidemic activity of the drugs were comparable to that of the Standard drug in all aspects and that it showed an enhanced capability in elevating the HDL levels than the standard drug. [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"} represents the graphical representation of the effect of drug on lipid parameters, percentage protection, HDL Ratio and Atherogenic index in different groups respectively.Fig. 1Effect of the drug on serum lipid levels.Fig. 2Percentage protection of the drug in various groups.Fig. 3Atherogenic indices in various groups after drug treatment.

4. Discussion {#s0040}
=============

Cholesterol build up in coronary arteries ends in fatal clinical events, which ranks higher than the mortalities from all types of cancers put together. The cholesterol homoeostasis is maintained by the lipoproteins, which dismantles the excess intracellular cholesterol into packets of lipoproteins circulating in blood. This event is pivotal in the development of atherosclerotic plaques subsequently ending in coronary artery disease ([@b0060]). So, the cholesterol along with their lipoprotein levels helps in prediction and clinically gauging cardiovascular events. Among the lipoproteins, High density lipoproteins (HDL) promotes vascular health by extracting cholesterol from tissues and atheroscelerotic plaques and delivers it back to the liver (Reverse cholesterol Transport) ([@b0025]). The drug combination at a dose of 1080 mg/kg and 2160 mg/kg body weight significantly elevated the HDL levels in the experimental rats (p \< 0.05). This result shows that the drug combination is a cardioprotective agent and accelerates the Reverse Cholesterol transport.

Low density lipoproteins (LDL) contributes to the formation of atherosclerotic plaques by binding to the connective tissue in the intimal layers of arteries ([@b0115]). Elevated levels of LDL cholesterol above 100 mg/dl is considered as the primary risk factor for CAD. The drug combination at both effective and double doses reduced the LDL levels significantly at p \< 0.01 and p \< 0.05 respectively. The result shows that the drug combination improves the atherosclerotic changes induced by the endothelium mediated vascular response in rats. Our study proves the significant result of the drug combination to reduce the LDL cholesterol significantly when compared to the normal rats.

Hypertriglyceridemia is considered as an independent risk factor for CVD. Fasting triglyceride measurement is important for evaluating the risk of heart disease especially in cases suffering from diabetes, glucose intolerance, insulin resistance syndrome and low HDL levels ([@b0070]). Increased secretion of TG rich VLDL particles lead to increase in small dense LDL production associated with decrease in HDL with resultant atherosclerotic plaque development. The study drug combination at a dose of 1080 mg/kg and 2160 mg/kg body weight significantly reduced the serum triglyceride levels (p \< 0.05). Our study proves the efficacy of the drug combination in reducing the independent risk factor for CVD, hypertriglyceridemia. The study also showed significant statistical reduction in VLDL levels (p \< 0.05) in both effective and double doses.

Various indices and ratios of different lipoproteins also play an important role in the estimation of cardiovascular risks. These indices termed Atherogenic indices were calculated either by computing any of the following ratios; viz, Castelli Risk Index I (CRI-I), Non HDL C/HDL, Castelli risk Index II (CRI-II), TG/HDL, Atherogenic coefficient and Atherogenic Index of Plasma (AIP). A total cholesterol/HDL ratio (CRI-I) ≤ 3 is considered low risk, and a value above 4.5 is a moderate risk while a value \>8 is considered high risk for developing coronary heart disease ([@b0010]). The effective and double doses of the study drug had significantly reduced the CRI-I ratio (p \< 0.01) when compared to normal and standard drugs. The Canadian Working group report considers CRI-I ratio as a secondary goal of therapy as it is more sensitive and specific index of cardiovascular risk than total cholesterol ([@b0055]). The ratio of LDLc to HDLc is termed Castelli Risk Index-II(CRI-II), along with CRI-I, CRI-II are strong predictors of coronary heart disease ([@b0005]). In this study both effective and double doses of the drug significantly reduced the CRI-II levels (p \< 0.01). Non-HDL Cholesterol index is considered as a better predictor of cardiovascular disease risk than the Triglyceride levels. In our study, Non-HDL c/HDL ratio decreased significantly (p \< 0.01) in effective dose as well as the double dose groups compared to the normal animals. The Atherogenic Index of Plasma (AIP) calculated as (log TG)/HDLc is considered a strong predictor for infarction ([@b0050]). The study drug at effective dose reduced AIP significantly at p \< 0.05. The double dose group, however, did not give a statistically significant result in AIP ratio. A Triglyceride based Atherogenic Index have more value in assessing cardiovascular risk than other indices ([@b0070]). The drug combination significantly reduced the TG/HDL ratio by the effective and double doses at p \< 0.01 and p \< 0.05 levels respectively. The percentage of protection from atherogenesis provided by the formulation was computed using the concomitant increase in plasma HDL. A 1% decrease in HDL escalates the risk of heart disease by 3--4% ([@b0020]). Cholestyramine, the standard group offered 39.4% protection when compared to normal animals. The effective dose of the drug and the double dose offered 51.2% and 45.8% protection respectively.

Mung beans have proved efficacy in normalizing insulin sensitivity, plasma lipid profile and triglyceride levels by its protein isolates. It showed significant scavenging activity against reactive oxygen and nitrogen species and inhibited LDL oxidation. The multiple pharmacological activities like antioxidant, antimicrobial, anti-inflammatory, antitumor and regulation of lipid metabolism are attributed to the presence of high levels of phytoconstituents like proteins, amino acids, oligosaccharides and polyphenols ([@b0100]). Sprouted mung bean shows enhanced biological activities because of the activation of biosynthetic enzymes resulting in abundant availability of secondary metabolites after germination. Thus the nutritional and medicinal qualities of mung beans are improved by sprouting ([@b0030]). Though a staple food across many countries, the consumption of mung bean is associated with flatulence in many due to the presence of Oligosaccharides, like raffinose, stachyose and verbascose present in raw seeds, which are removed to a greater extend by presoaking or germination as they are water soluble ([@b0110]).

Amorphophallus is an edible corm used as a vegetable in tropical and sub-tropical countries with considerable medicinal properties. It has a wealth of phyto-constituents which includes sugars like glucose, galactose and rhamnose, glucomannan, flavonoids, phenols, coumarins, terpenoids, sterols and alkaloids. A diet rich in glucomannan reduced the levels of hormone, leptin, derived from adipocytes, which regulates body mass. The hypolipidemic effect of glucomannan derived from Amorphophallus was similar in action to statins; competitive inhibition of HMG-CoA reductase and reducing LDL synthesis. Thus the combination of Mung bean and Yam proves to act synergistically in reducing the lipid levels in dyslipidemia.

5. Conclusion {#s0045}
=============

Considering the results obtained from this study, the combination of mung bean and yam significantly reduced the serum lipid levels as well as the atherogenic indices in albino rats in comparison to the, bile acid sequestering agent, Cholestyramine as standard. Both mung bean and yam has been traditionally used as a food item throughout Asia. The combination provides a hope in reducing the high CAD risk among Asians by becoming a mainstay of non-pharmacological agents against dyslipidemia.
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[^1]: Values are expressed as Mean ± SEM, (n = 6), serum lipid levels are expressed in mg/dl. One-way ANOVA followed by Dunnet's Multiple comparison post hoc test have been performed with the normal group and Standard group.

[^2]: *p* \< *0.05*.

[^3]: *p* \< *0.01*.

[^4]: *p* \< *0.001*.

[^5]: *p* \> *0.05*.

[^6]: Values are expressed as Mean ± SEM, (n = 6). One-way ANOVA followed by Dunnet's Multiple comparison post hoc test have been performed with the normal group and Standard group.

[^7]: *p* \< *0.05*.

[^8]: *p* \< *0.01*.

[^9]: *p* \< *0.001*.

[^10]: *p* \> *0.05*.
